Bioengineering startup AltPep advances technology for the early detection and treatment of Alzheimer’s and other amyloid diseases.
Read BioSpace article: Seattle Startup Chases Alzheimer’s with $23 Million Series A
AltPep announces closing $23.150 million Series A investment round, let by Matrix Capital Management with significant participation by Alexandria Venture Investments. In conjunction with the financing, David Goel, Managing General Partner and Co-founder of Matrix...
Read Geekwire article: Seattle biotech startup AltPep raises $23.1M to tackle Alzheimer’s and related diseases
Chad is the co-founder and CEO of Adaptive Biotechnologies, a commercial-stage biotech company in Seattle that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease.